Radioligand therapy continues to gain momentum as a transformative approach in oncology. A recent analysis of PubMed publications highlights a steady and significant increase in primary articles on clinical therapeutic radionuclides between 2000 and 2024.
This trend reflects the growing scientific and clinical interest in systematic radioligand therapy (SRT), particularly as new radionuclides enter development and move toward the market. Each wave of innovation brings a broader range of applications, expanding the evidence base and accelerating adoption in clinical practice.
Hits of PubMed Primary Articles on All Clinical Therapeutic Radionuclides from 2000 to 2024
The data, adapted from Radiotheranostic landscape: A review of clinical and preclinical development (Tran et al., 2025), underscores the rapid progress being made in the field and signals an exciting future for radiotheranostics.
Interested in how these trends may impact your business? Connect with Bracken to learn how our team can guide your next steps in radiopharmaceutical development.
Reference: Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: A review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025.
